The transparency discussion is undermined by the fixation on outcomes and the focus on publishing information that realistically adds almost nothing to the community's understanding of how medicines are funded in Australia. This fixation is compounded by a power imbalance that sees all the pressure on the industry when it comes to transparency while 'backroom' processes remain a mysterious locked box.
Transparency of process is more important than transparency of outcome
January 23, 2020 Latest NewsCommentNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 12 December
December 12, 2025 - - Podcast -
Medicines Australia gains a new voice with Vertex joining the association
December 11, 2025 - - Latest News -
BMS marks 70 years in Australia with renewed commitment to innovation and access
December 11, 2025 - - Latest News -
Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children
December 11, 2025 - - Latest News -
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - - Latest News -
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - - Latest News -
TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN
December 10, 2025 - - Australian Biotech
